We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for pegcetacoplan (Swedish Orphan Biovitrum Pty Ltd)
Active ingredients
pegcetacoplan
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
solution for injection
Indication
For the treatment of adults and adolescents aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulopathy (IC-MPGN).
Therapeutic area
Nephrology